Evidence map›Paper›PMID 30820696›Full record

ArticleClinical rheumatology2019

Health-related quality of life in patients with systemic lupus erythematosus: a Spanish study based on patient reports.

J A Román Ivorra, N Fernández-Llanio-Comella, A San-Martín-Álvarez, P Vela-Casasempere, I Saurí-Ferrer, S González-de-Julián, D Vivas-Consuelo

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Observational
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Living with Systematic Lupus Erythematosus: A Profile of Young Female Patients.International journal of environmental research and public health · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

J A Román IvorraHospital Universitario y Politécnico La Fe, Valencia, Spain.
N Fernández-Llanio-ComellaHospital Arnau de Vilanova, Valencia, Spain.
A San-Martín-ÁlvarezHospital General Universitario de Elda, Alicante, Spain.
P Vela-CasasempereHospital General Universitario de Alicante, Alicante, Spain.
I Saurí-FerrerInstituto de Investigación Sanitaria (INCLIVA), Valencia, Spain.
S González-de-JuliánCentro de Ingeniería Económica (INECO), Universitat Politècnica de València (UPV), Valencia, Spain.
D Vivas-ConsueloCentro de Ingeniería Económica (INECO), Universitat Politècnica de València (UPV), Valencia, Spain. dvivas@upv.es.ORCID http://orcid.org/0000-0003-2945-7525

Funding

UCB Pharma, S.L. -
6 · The paper itself

Abstract

INTRODUCTION AND

objectivesSystemic lupus erythematosus (SLE) is a disease that significantly affects the quality of life and welfare of patients. SLE patients can be classified into multimorbidity levels using Clinical Risk Groups (CRGs) to help to incorporate predictive models of health needs. The goal of this study was to correlate CRGs with health-related quality of life (HR-QoL) and costs in SLE patients.

methodsA questionnaire was administered to SLE patients in four hospital centers of the Valencian Community (Spain) between October 2015 and March 2016. The factors studied included HR-QoL (EQ-5D-5L and VAS), disease activity (SLAI/SELENA), damage (SLICC/ACR), and severity (IGK).

resultsThe patients (N = 190, 92.06% female, age (mean ± SD) 47.23 ± 13.43 years) were sorted according to health status in nine CRGs. We found that most SLE patients (> 70%) were in CRGs 5 and 6. The main HR-QoL issues in these patients were related to mobility, ability to perform usual activities, and pain/discomfort. The scores (mean ± SD) for EQ-5D-5L and VAS were 0.74 ± 0.25 and 65.67 ± 23.52, respectively. We found that the age of the patients negatively affected their HR-QoL (r = - 0.266). SLE direct costs per patient increased with each CRG group, representing 71.92% of the total costs, while indirect costs were highly variable. The average cost per patient with SLE amounted to €8432.85 (year 2014).

conclusionsPatients' quality of life is related with age, disease activity, damage, and severity. Age was the parameter which most affects HR-QoL. Most costs of SLE are concentrated in two CRGs in which the HR-QoL deteriorates sharply.

Indexed as

Cost of IllnessQuality of LifeAdultFemaleHealth Care CostsHealth StatusHumansLupus Erythematosus, SystemicMaleMiddle AgedPatient Reported Outcome MeasuresSeverity of Illness IndexSpainVisual Analog ScaleHealth-related quality of lifePatient costsPatient-reported outcomesSystemic lupus erythematosus

Identifiers

PMID30820696

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.